The impact of quality-adjusted life years on evaluating COVID-19 mitigation strategies: lessons from age-specific vaccination roll-out and variants of concern in Belgium (2020-2022)

Table 1 Vaccine- and infection-induced immunity levels against infection and hospital admissions by VOC and vaccine schedule. The waning-related submodels (e.g. waning₁) of Fig. 2 are listed here. The waning rate is the proportion of individuals moving from full protection to reduced protection per unit of time, which is inversely related to the average duration of protection. References and assumptions are provided at the bottom of the table

Vaccine type	Waning	Alpha		Delta		Omicron
	rate	Infect.^a	Hosp.^a	Infect.^b	Hosp.^c	Infect.^b	Hosp.^d
Adeno: 1st dose	-	49%	76%	43%	76%^e	18%	65%^f
Adeno: 2nd dose	-	74%	86%	83%	95%	49%	81%^f
mRNA: 1st dose	-	48%	83%	72%	79%^e	32%	65%^e
mRNA: 2nd dose	-	94%	95%	91%	99%	66%	81%
mRNA: booster dose	-	-	-	95%	99%^g	67%	90%
Waned immunity after two doses \((waning_3)\)	\(\frac{1}{90 days}\)	63%	92%	63%	92%	9%	57%
Waned immunity after booster dose \((waning_4)\)	\(\frac{1}{90 days}\)	-	-	89%	92%^h	46%	81%^h
Waned immunity after infection \((waning_1)\)	\(\frac{1}{90 days}\)	63%^g	76%ⁱ	63%^g	79%ⁱ	9%^g	72%ⁱ
Waned immunity after infection and vaccination \((waning_2)\)	\(\frac{1}{90 days}\)	94%^j	95%^j	95%^j	99%^j	67%^j	90%^j

^aBernal et al. [2]; ^bAndrews et al. [3]; ^cAndrews et al. [6]; ^dCDC report,2022; ^eAssumed equal to 80% of 2 doses; ^fAssumed equal to mRNA; ^gAssumed equal after 2 mRNA doses; ^hAssumed 90% of booster mRNA dose; ⁱAssumed 80% of booster mRNA dose; ^jAssumed equal after booster mRNA dose

ISSN: 1471-2458